Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427782 | 0.75 | AHR (0.36) | CCNA2CDK2CCNA1 | |
| SCHEMBL1760511 | 0.75 | IDO1 (0.37) | CDK2CYP11B1CYP11B2 | |
| SCHEMBL18839387 | 0.75 | PDE3B (0.34) | CCNA2CDK2CCNA1 | |
| SCHEMBL2122482 | 0.73 | CCNA2 (0.32) | CCNA2CDK2CCNA1 | |
| SCHEMBL433698 | 0.72 | ADRA2A (0.49) | CYP11B1CYP11B2 | |
| SCHEMBL29941234 | 0.70 | MAPK10 (0.45) | CCNA2CDK2CCNA1 | |
| SCHEMBL3085133 | 0.69 | KDM4A (0.33) | — | |
| SCHEMBL8565229 | 0.69 | AHR (0.37) | — | |
| SCHEMBL12276833 | 0.69 | CCNA2 (0.33) | CCNA2CDK2CCNA1 | |
| Urea SCHEMBL1549376 | 0.68 | CCNA2 (0.43) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4324887-B1 | DISPERSION PAINT | BRILLUX GMBH & CO KG (DE) | 2026-04-29 | — | — | EP | claimed |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | claimed |
| CN-117683035-A | Synthesis method of substituted pyrazoloquinazoline derivative | 成都睿智化学研究有限公司 | 2024-03-12 | — | — | CN | claimed |
| EP-3810700-B1 | DISPERSION PAINT | BRILLUX GMBH & CO KG (DE) | 2023-08-02 | — | — | EP | claimed |
| CN-116528871-A | Pyrazoloquinazoline compound, and preparation method and application thereof | 恒元生物医药科技(苏州)有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116332942-A | Synthesis method of substituted pyrazolo-quinazoline derivative | 合肥工业大学 | 2023-06-27 | — | — | CN | claimed |
| WO-2022143576-A1 | PYRAZOLOQUINAZOLINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 恒元生物医药科技(苏州)有限公司 | 2022-07-07 | — | — | WO | claimed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | claimed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | claimed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | claimed |
| US-8541429-B2 | Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| CN-102079746-A | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2011-06-01 | — | — | CN | claimed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | claimed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | claimed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | claimed |
| JP-2007502851-A | — | — | 2007-02-15 | — | — | JP | claimed |
| CN-1826343-A | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | PHARMACIA ITALIA SPA (IT) | 2006-08-30 | — | — | CN | claimed |
| EP-1636236-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-03-22 | — | — | EP | claimed |
| WO-2004104007-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-12-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1207/4885CDK2 49/4885CCNA1 933/4885 |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1207/4885CDK2 49/4885CCNA1 933/4885 |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP3K19 | CCNA2 1362/4885CDK2 52/4885CCNA1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.